natgillin/translations-raw huggingface dataset:
Arter, for hvilke erhvervet resistens kan udgøre et problem
Species for which acquired resistance may be a problem
Arter, for hvilke erhvervet resistens kan være et problem:
Species for which acquired resistance may be a problem:
Arteriel aneurisme og kendt arteriel/venøs misdannelse
Arterial aneurysm and known arterial/venous malformation
Arteriel blødning
Arterial bleeding
Arteriel blødning.
Arterial bleeding.
arteriel hypertension
pulmonary arterial
arteriel hypertension administreret
pulmonary arterial hypertension
ARTERIEL HYPERTENSION i
Also see PULMONARY
arteriel nyretrombose*, nefritis, nefrosclerose, tubulær artrofi, hæmoragisk cystitis, nyrefibrose
renal artery thrombosis*, nephritis, nephrosclerosis, renal tubular atrophy, cystitis haemorrhagic, kidney fibrosis
Arteriel tromboemboli (1)
Arterial thromboembolism (1)
Arteriel tromboemboli (Akut) myokardie-infarkt*†
Arterial thromboembolism (Acute) myocardial infarction
Arteriel tromboemboli – nuværende arteriel tromboemboli, tidligere arteriel tromboemboli (f.eks. myokardieinfarkt) eller prodromalsymptom (f.eks. angina pectoris)
Arterial thromboembolism – current arterial thromboembolism, history of arterial thromboembolism (e.g. myocardial infarction) or prodromal condition (e.g. angina pectoris);
Arteriel tromboemboli – nuværende arteriel tromboemboli, tidligere arteriel tromboemboli (f.eks. myokardieinfarkt) eller prodromalsymptom (f.eks. angina pectoris).
Arterial thromboembolism - current arterial thromboembolism, history of arterial thromboembolism (e.g. myocardial infarction) or prodromal condition (e.g. angina pectoris).
Arteriel trombose
arterial thrombosis
Arterielle og venøse tromboser og okklusioner, herunder letal myokardieinfarkt, apopleksi, retinale vaskulære okklusioner i visse tilfælde forbundet med permanent synsnedsættelse eller synstab, stenose i de store hjernearterier, svær perifer karsygdom, nyrearteriestenose (forbundet med forværret, labil eller behandlingsresistent hypertension) og behov for akut revaskulariserende indgreb, er forekommet hos patienter behandlet med Iclusig.
Arterial and venous thrombosis and occlusions, including fatal myocardial infarction, stroke, retinal vascular occlusions associated in some cases with permanent visual impairment or vision loss, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, renal artery stenosis (associated with worsening, labile or treatment-resistant hypertension), and the need for urgent revascularization procedures have occurred in Iclusig-treated patients.
arterielle tromboemboliske bivirkningera
Arterial thromboembolic reactions a
Arterielle tromboemboliske hændelser (ATE’er) er bivirkninger, der potentielt er forbundet med systemisk VEGF-inhibition.
Arterial thromboembolic events (ATEs) are adverse events potentially related to systemic VEGF inhibition.
Arterielle tromboemboliske hændelser (ATE’er) er bivirkninger, der potentielt kan være relateret til systemisk VEGF-hæmning.
Arterial thromboembolic events (ATEs) are adverse events potentially related to systemic VEGF inhibition.
Arterielle tromboemboliske hændelser (myokardieinfarkt, cerebralt infarkt, cerebral iskæmi, okklusion af cerebralarterie, cerebrovaskulært tilfælde, trombose i arteria renalis, perifær iskæmi, perifær arteriel trombose og intestinal iskæmi)
Arterial thromboembolic events (myocardial infarction, cerebral infarction, cerebral ischaemia, cerebral artery occlusion, cerebrovascular accident, renal artery thrombosis, peripheral ischaemia, peripheral arterial thrombosis and intestinal ischaemia)
Arterielle tromboemboliske hændelserc, d, j
Arterial embolic and thrombotic eventsc,d,j
Arterierne blokeres af en blodprop ("arterielle tromboemboliske hændelser"):
Blocking of the arteries by a blood clot (‘arterial thromboembolic events’):
Arteriespidsen kan fjernes, når koagulationen er vendt tilbage til det normale, svarende til at aktiveret koagulationstid (ACT) er mindre end
Arterial sheaths may be removed when coagulation has returned to normal (e.g. when activated clotting time (ACT) is less than 180 seconds (usually 2
arteriosklerotisk
Arteriosclerotic
arteriosklerotisk
haemorrhage,
Arthralgi (G3/4: 0,3 %);
Myalgia (G3/4: 2%);
Arthralgi Arthritis / Psoriatisk arthritis (forvær- ring/ opblussen)
Arthralgia Arthritis / Psoriatic arthritis (exacerbation/ flare)
arthralgi, muskelspasmer (kramper i benene), myalgi
arthralgia, muscle spasms (cramps in legs), myalgia
Arthritis / Psoriatisk arthritis:
Arthritis / Psoriatic arthritis:
arthritis psoriatica hos voksne, der ikke har reageret tilstrækkeligt på andre behandlinger
psoriatic arthritis in adults who have not responded adequately to other treatments;
Arthritis psoriatica: Leflunomidbehandling indledes med en startdosis på 100 mg en gang daglig i 3 dage.
In psoriatic arthritis: leflunomide therapy is started with a loading dose of 100 mg once daily for 3 days.
Arthritis psoriatica: Leflunomidbehandling indledes sædvanligvis med en startdosis på 100 mg i 3 dage.
In psoriatic arthritis: leflunomide therapy is started with a loading dose of 100 mg once daily for 3 days.
Arthritis urica: Den anbefalede dosis til patienter med let nedsat leverfunktion er 80 mg.
Gout: The recommended dose in patients with mild hepatic impairment is 80 mg.
arthritis, muskelspasmer, nakkesmerter, nattekramper
Arthritis, muscle spasms, neck pain, night cramps
Artralgi
Common
Artralgi
Irritability
Artralgi (G3/4: 0,2%)
Arthralgia (G3/4: 0.2%)
Artralgi (G3/4: 0,3 %); Myalgi (G3/4: 0,3 %)
Myalgia (G3/4: 0.7%);
Artralgi (G3/4: 0,3%);
Arthralgia (G3/4: 0.3%);
Artralgi (G3/4: 1 %)
Arthralgia (G3/4: 1%)
Artralgi (G3/4: 1%)
Arthralgia (G3/4: 1%)
artralgi (ledsmerter)
arthralgia (joint pain)
Artralgi (N), myalgi (N)
Arthralgia (N), Myalgia (N)
Artralgi *
Arthralgia
Artralgi Aksillær masse Hævede led Myalgi
Arthralgia Axillary mass Joint swelling Myalgia
Artralgi Myalgi Muskelspasmer
Arthralgia Myalgia Muscle spasms
Artralgi Myalgi Rygsmerter
Myalgia Back pain
Artralgi Myalgi Rygsmerter Hævelse af led
Arthralgia Myalgia Back pain Joint swelling
Artralgi og myalgi (20,4 %) (G3/4: 1,0 %)
Arthralgia and myalgia (20.4%) (G3/4: 1.0%)
Artralgi og rygsmerter
Arthralgia and back pain
Artralgi Rygsmerte Muskelstivhed Muskelsvaghed
Arthralgia Back pain Muscle rigidity
Artralgi Rygsmerter
Arthralgia Back pain
Artralgi*
Arthralgi a
Artralgi*
Arthralgia
Artralgi* Myalgi*
Arthralgia* Myalgia
Artralgi*, myalgi*
Arthralgia*, Myalgia
Artralgi, artrit, rygsmerter, lændesmerter, smerter i knogler, led og muskler, myalgi, nakkesmerter, osteopeni, smerter i ekstremiteterne, tendinitis, rabdomyolyse
arthralgia, arthritis, back pain, flank pain, musculoskeletal pain, myalgia, neck pain, osteopenia, pain in extremity, tendonitis, rhabdomyolysis
Artralgi, ekstremitetssmerter, muskelsvaghed
Arthralgia, Pain in extremity, Muscular weakness
Artralgi, Knoglesmerter, Myalgi, Ekstremitetssme rter
Arthralgia, Bone pain, Myalgia, Pain in extremity
Artralgi, muskelkramper, muskelstramhed, nakkesmerter, smerter i lemmer
Arthralgia, muscle spasms, muscle tightness, neck pain, pain in extremity
Artralgi, muskellidelser
arthralgia, muscle disorders
Artralgi, muskelsmerter, hævede led
Arthralgia, myalgia, joint swelling
artralgi, muskelspasmer
arthralgia, muscle spasms
artralgi, muskelspasmer (kramper i benene), myalgi
arthralgia, muscle spasms (cramps in legs), myalgia
Artralgi, muskuloskeletale smerter
Arthralgia, musculoskeletal pain
artralgi, muskuloskeletale smerter (herunder ryg, knogler og ekstremiteter)
arthralgia, musculoskeletal pain (includes
Artralgi, Myalgi*
Arthralgia, Myalgia
Artralgi, myalgi, muskelspasmer, knoglesmerter, rygsmerter, nakkesmerter, ekstremitetssmerter
Arthralgia, Myalgia, Muscle spasms, Bone pain, Back pain, Neck pain, Pain in extremity
artralgi, myalgi, muskelsvaghed, muskulosketal stivhed, muskelspasmer
arthralgia, myalgia, muscular weakness, musculoskeletal stiffness, muscle spasm
Artralgi, myalgi, muskuloskeletal smerte
Arthralgia, myalgia, musculoskeletal pain
artralgi, myalgi, muskuloskeletale smerter, muskelkramper
arthralgia, myalgia, musculoskeletal pain, muscle spasms
Artralgi, myalgi, muskuloskeletale smerter, muskelkramper, muskuloskeletal stivhed
Arthralgia, Myalgia, Musculoskele tal pain, Muscle cramp, Musculoskele tal stiffness
Artralgi, myalgi, smerter i ekstremiteter, muskuloskeletal smerte, ryg- smerter
Arthralgia, myalgia, pain in extremity, musculoskeletal pain, back pain
Artralgi, myalgi, smerter i ekstremiteter1
Arthralgia, Myalgia, Pain in extremity1
artralgi, myositis
Arthralgia, myositis
Artralgi, rygsmerter*
Arthralgia, backache
Artralgi, rygsmerter, muskelspasmer, muskelsvækkelse, muskuloskeletale smerter, myalgi, nakkesmerter, smerter i ekstremiteterne
Arthralgia, back pain, muscle spasms, muscular weakness, musculoskeletal pain, myalgia, neck pain, pain in extremity
artralgi, rygsmerter, muskelspasmer, myalgi
arthralgia, back pain, muscle spasms, myalgia
artralgi, rygsmerter, muskelspasmer, smerter i lemmer
arthralgia, back pain, muscle spasms, pain in limb
Artralgi, rygsmerter, muskuloskeletale brystsmerter
Arthralgia, back pain, musculoskeletal chest pain
Artralgi, rygsmerter, myalgiD
Arthralgia, back pain, myalgiaD
artralgi, rygsmerter, smerte i ekstremiteterne
arthralgia, back pain, pain in extremity
Artralgi2, muskelforstyrrelser1
arthralgia2, muscle disorders1
Artralgi9
Arthralgia 9
Artralgi9
Arthralgia9
Artralgia, artritis, myalgi, ekstremitetssmerter
Arthralgia, Arthritis, Myalgia, Pain in extremity
Artralgia,am, hævede ankleram
Arthralgiaa,am, ankle swellingam
Artralgier
56 (17.4)
Artralgier
Hyperbilirubinaemia
artralgier / muskulo- skeletale smerter, osteoartrit, bursitis
arthralgia / musculoskeletal pain, osteoarthritis, bursitis
artrieflimren/hjerteflimren
atrial fibrillation/atrial flutter
Artrit, rygsmerter, lændesmerter, smerter i knogler, led og muskler, myalgi, nakkesmerter, osteopeni, smerter i ekstremiteterne, tendinitis, rabdomyolyse
arthritis, back pain, flank pain, musculoskeletal pain, myalgia, neck pain, osteopenia, pain in extremity, tendonitis, rhabdomyolysis
artritis
arthritis
artritis (hævede led, polyartritis og ledeffusion)
arthritis (joint swelling, polyarthritis and joint effusion)
Artritis Artropati Knoglecyste
Arthrofibrosis,
artritis urica, anoreksi, nedsat appetit, vægttab, vægtstigning, hyperglykæmi, insulinresistens, nedsat HDL, øget appetit, polydipsi, øget lactatdehydrogenase i blodet
gout, anorexia, decreased appetite, decreased weight, increased weight, hyperglycaemia, insulin resistance, decreased high density lipoprotein, increased appetite, polydipsia, increased blood lactate dehydrogenase
Artritis, ubehag i lemmerne, muskel- spasmer, muskelspænding, muskuloskeletal stivhed, myalgi, muskelsmerter, nakkesmerter, tyngde fornemmelse, akut myositis og kronisk myositis
Arthritis, Limb discomfort, Muscle spasms, Muscle strain, Musculoskeletal stiffness, Myalgia, Muscle pain, Neck pain, Sensation of heaviness, Acute myositis and chronic myositis
Artrit† og/eller artralgi† (i reglen forbigående og sjældent kronisk), myalgi
Arthritis† and/or Arthralgia† (usually transient and rarely chronic), Myalgia
Artrofibrose
Arthrofibrosis
Artrofibrose Synovitis Tendonitis Ledblødning Artralgi Ledeffusion Hævelse i led Stivhed i led Knogleødem
Arthrofibrosis Synovitis Tendonitis Haemarthrosis Arthralgia Joint effusion Joint swelling Joint stiffness Bone oedema
Artropati*
arthropathy
Artropati, bursitis, coccygodyni, costochondritis, dactylitis, exostose, hæmartrose, kontraktur af ekstremitet, ledstivhed, muskelkontraktur, muskeltrækninger, muskuloskeletale gener, periartrit, rheumatoid artrit, rotator cuff-syndrom, smerter i kæbe, tendosynovitis, trommestikfingre
Arthropathy, bursitis, clubbing, coccydynia, costochondritis, dactylitis, exostosis, extremity contracture, haemarthrosis, joint stiffness, muscle contracture, muscle twitching, musculoskeletal discomfort, pain in jaw, periarthritis, rheumatoid arthritis, rotator cuff syndrome, tenosynovitis
Arvelig eller idiopatisk angioødem.
Hereditary or idiopathic angioedema
arveligt angioødem
hereditary angioedema
arveligt angioødem
hereditary angioedema,
arveligt angioødem.
hereditary angioedema
arvæv i penis
car tissue in penis
arytmi
arrhythmia
arytmi
tachycardia
Arytmi (G3/4: 0,2 %)
Arrhythmia (G3/4: 0.2%);
Arytmi (G3/4: 0,2 %);
Arrhythmia (G3/4: 0.2%)
Arytmi (G3/4: 0,2%)
Arrhythmia (G3/4: 0.2%)
Arytmi (G3/4: 0,6
Arrhythmia (G3/4: 0.6%)
Arytmi (G3/4: 0,6 %)
Ischemia myocardial
Arytmi (G3/4: 0,6%)
Arrhythmia (G3/4: 0.6%)
Arytmi (G3/4: 0,7
Arrhythmia (G3/4: 0.7%)
Arytmi (G3/4: 0,7 %)
Arrhythmia (G3/4:
Arytmi (G3/4: 0,7 %)
Arrhythmia (G3/4:0.7%)
Arytmi (G3/4: 0,7 %)
Arrythmia (G3/4:0.7%)
Arytmi (G3/4: 0,7 %)
Cardiac disorders
Arytmi (G3/4: 1,0 %)
Arrhythmia (G3/4: 1.0%).
Arytmi (G3/4: 2,0%)
Arrhythmia (G3/4: 2.0%)
arytmi (herunder ventrikulær arytmi)c, atrieflimren
arrhythmia (including ventricular arrhythmia)c, atrial fibrillation
Arytmi Atrieflimren Kardiomegali Perikardie-effusion Perikardit
Arrhythmia Atrial fibrillation Cardiomegaly Pericardial effusion Pericarditis
arytmi,
arrhythmia,
arytmi, artrieflimren
arrhythmia, atrial fibrillation
Arytmi, forlænget QT-interval, atrieflagren, ventrikulære ekstrasystoler
Arrhythmia, QT prolongation, Atrial flutter, Ventricular extrasystoles
Arytmier
Arrhythmias
Arytmier (f.eks.
Arrhythmias (e.g.
arytmier,
(predominatel
arytmier, takykardi, palpitationer
arrhythmias, tachycardia, palpitations
Arytmierne forsvandt spontant, og begge frivillige forsøgspersoner kom sig uden følger.
The arrhythmias spontaneously resolved, and both volunteers recovered without sequelae.
Arzerra 1.000 mg fås i pakninger, der indeholder 1 hætteglas.
Arzerra 1,000 mg is available in a pack containing 1 vial.
Arzerra 1.000 mg koncentrat til infusionsvæske, opløsning
Arzerra 1,000 mg concentrate for solution for infusion.
Arzerra 1.000 mg sterilt koncentrat.
Arzerra 1,000 mg sterile concentrate Ofatumumab
Arzerra 100 mg fås i pakninger, der indeholder 3.
Arzerra 100 mg is available in a pack containing 3 vials.
Arzerra 100 mg koncentrat til infusionsvæske, opløsning
Arzerra 100 mg concentrate for solution for infusion.
Arzerra 100 mg koncentrat til infusionsvæske, opløsning Arzerra 1.000 mg koncentrat til infusionsvæske, opløsning
Arzerra 100 mg concentrate for solution for infusion Arzerra 1,000 mg concentrate for solution for infusion
Arzerra 100 mg sterilt koncentrat.
Arzerra 100 mg sterile concentrate Ofatumumab
Arzerra anvendes til behandling af kronisk lymfatisk leukæmi (CLL), en kræfttype i de hvide blodlegemer (lymfocytterne).
Arzerra is used to treat chronic lymphocytic leukaemia (CLL), a cancer of a type of white blood cells called lymphocytes.
Arzerra blev administreret som monoterapi til 223 patienter med refraktær CLL (studie Hx-CD20- 406).
Arzerra was administered as a monotherapy to 223 patients with refractory CLL (study Hx-CD20- 406).
Arzerra blev desuden undersøgt i en hovedundersøgelse med 447 ikke tidligere behandlede patienter, som ikke kunne behandles med fludarabin.
Arzerra has also been studied in one main study involving 447 previously untreated patients who could not be treated with fludarabine-based therapy.
Arzerra blev også givet til en gruppe af patienter (n=112) med lymfadenopati med stor tumorbyrde (defineret som mindst én lymfeknude på > 5 cm), som var refraktære over for fludarabin.
Arzerra was also given to a group of patients (n=112) with bulky lymphadenopathy (defined as at least one lymph node >5 cm) who were also refractory to fludarabine.
Arzerra bør ikke anvendes til børn under 18 år på grund af utilstrækkelig dokumentation for sikkerhed og/eller effekt.
Arzerra is not recommended for use in children below 18 years due to insufficient data on safety and/or efficacy.
Arzerra bør normalt ikke anvendes til behandling under graviditet.
Arzerra is not usually recommended for use during pregnancy.
Arzerra er et farveløst til svagt gult koncentrat til infusionsvæske.
Arzerra is a colourless to pale yellow concentrate for solution for infusion.
Arzerra er et kræftlægemiddel, der indeholder det aktive stof ofatumumab.
Arzerra is a cancer medicine that contains the active substance ofatumumab.
Arzerra er i kombination med chlorambucil eller bendamustin indiceret til behandling af patienter med CLL, der ikke tidligere har fået behandling, og som ikke er egnet til behandling baseret på fludarabin.
Arzerra in combination with chlorambucil or bendamustine is indicated for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy.
Arzerra er indiceret til behandling af patienter med CLL, der er refraktære over for fludarabin og alemtuzumab.
Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.
Arzerra fås i pakninger med 1 hætteglas.
Arzerra is available in 1-vial packs.
Arzerra gives i en vene (intravenøst) som en infusion (et drop) over flere timer.
Arzerra is given into a vein (intravenously) as an infusion (a drip) over several hours.
Arzerra i kombination med chlorambucil blev sammenlignet med chlorambucil alene.
Arzerra given together with chlorambucil was compared with chlorambucil alone.
Arzerra i kombination med chlorambucil eller bendamustin er indiceret til behandling af patienter med CLL, der ikke tidligere har fået behandling og som ikke er egnet til fludarabinbehandling.
Arzerra in combination with chlorambucil or bendamustine is indicated for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy.
Arzerra må hverken blandes eller administreres med andre lægemidler eller infusionsvæsker.
Arzerra must not be mixed with, or administered as an infusion with other medicinal products or intravenous solutions.
Arzerra og chlorambucil (N=221)
Arzerra and Chlorambucil (N=221)
Arzerra påvirker sandsynligvis ikke din evne til at føre motorkøretøj eller betjene maskiner.
Arzerra is unlikely to affect your ability to drive or use machines
Arzerra skal administreres ved brug af en pumpe til intravenøs infusion.
Administer using an intravenous infusion pump.
Arzerra-koncentratet skal kontrolleres for fremmedlegemer og misfarvning inden fortyndingen.
Check the Arzerra concentrate for particulate matter and discoloration prior to dilution.
AS-studie 1 (MEASURE 1) evaluerede 371 patienter, hvoraf henholdsvis 14,8 % og 33,4 % fik samtidig MTX eller sulfasalazin.
AS Study 1 (MEASURE 1) evaluated 371 patients, of whom 14.8% and 33.4% used concomitant MTX or sulfasalazine, respectively.
AS-studie 2 (MEASURE 2) evaluerede 219 patienter, hvoraf henholdsvis 11,9 % og 14,2 % fik samtidig MTX eller sulfasalazin.
AS Study 2 (MEASURE 2) evaluated 219 patients, of whom 11.9% and 14.2% used concomitant MTX or sulfasalazine, respectively.
AS03-adjuvans bestående af squalen (10,69 mg), DL-α-tocopherol (11,86 mg) og polysorbat 80 (4,86 mg)
AS03 adjuvant composed of squalene (10.69 milligrams), DL--tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams)
AS03-adjuvans bestående af squalen (10,69 mg), DL-α-tocopherol (11,86 mg) og polysorbat 80 (4,86 mg).
AS03 adjuvant composed of squalene (10.69 milligrams), DL--tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams)
AS03-adjuveret vaccine indeholdende 3,75 µg HA fra A/California/7/2009 (H1N1)
AS03-containing vaccines containing 3.75 µg HA derived from A/California/7/2009 (H1N1)
ASA (75 - 100 mg daglig) bør indledes og fortsættes i kombination med clopidogrel (se afsnit 5.1).
ASA (75-100 mg daily) should be initiated and continued in combination with clopidogrel (see section 5.1).
ASA (75-100 mg per dag) moet gestart en voortgezet worden in combinatie met clopidogrel (zie rubriek 5.1).
ASA (75-100 mg daily) should be initiated and continued in combination with clopidogrel (see section 5.1).
ASA i Clopidogrel/Acetylsalicylsyre Zentiva hydrolyseres hurtigt i plasma til salicylsyre med en halveringstid på 0,3-0,4 timer for ASA-doser op til 75-100 mg.
The ASA in Clopidogrel/Acetylsalicylic acid Zentiva is rapidly hydrolyzed in plasma to salicylic acid, with a half-life of 0.3 to 0.4 hours for ASA doses from 75 to 100 mg.
ASA i kombinationen clopidogrel/acetylsalicylsyre hydrolyseres hurtigt i plasma til salicylsyre med en halveringstid på 0,3-0,4 timer for ASA-doser op til 75-100 mg.
The ASA in the combination of clopidogrel/acetylsalicylic acid is rapidly hydrolyzed in plasma to salicylic acid, with a half-life of 0.3 to 0.4 hours for ASA doses from 75 to 100 mg.
ASA- behandling (75-100 mg daglig) bør initieres og fortsættes i kombination med clopidogrel (se pkt.
ASA (75-100 mg daily) should be initiated and continued in combination with clopidogrel (see section 5.1).
ASA-behandling (75-100 mg daglig) bør initieres og fortsættes i kombination med clopidogrel (se pkt.
ASA (75-100 mg daily) should be initiated and continued in combination with clopidogrel (see section 5.1).
ASA-gruppen sammenlignet med placebo + ASA-gruppen (1,4 % versus 0,8 %, henholdsvis).
+ ASA treatment group compared to the placebo + ASA group (1.4% versus 0.8%, respectively).
ASAS 20-respons var forbedret ved uge 16 hos både anti-TNFα-naive patienter (68,2 % versus 31,1 %; p<0,05) og anti-TNFα-IR-patienter (50,0 % versus 24,1 %; p<0,05) for Cosentyx 150 mg sammenlignet med placebo.
ASAS 20 responses were improved at Week 16 in both anti-TNFα-naïve patients (68.2% versus 31.1%; p<0.05) and anti-TNFα-IR patients (50.0% versus 24.1%; p<0.05) for Cosentyx 150 mg compared with placebo, respectively.
ASAS 20-respons, %
ASAS 20 response,
ASAS 40-respons, %
ASAS 40 response,
ASAS 70 :
ASAS 70:
ASAS Partiel Remission
ASAS Partial Remission
ASAS Partiel Remission
p = 0.008
ASAS partiel remission, %
ASAS partial remission,
ASAT (SGOT), ALAT (SGPT) og -GT) før behandlingen indledes og med regelmæssige intervaller efter starten af Betaferon-behandlingen og med mellemrum derefter, hvis der ikke foreligger nogen kliniske symptomer.
AST (SGOT), ALT (SGPT) and -GT), are recommended prior to initiation and at regular intervals following introduction of Betaferon therapy, and then periodically thereafter in the absence of clinical symptoms.
ASAT = aspartat-aminotransferase; ULN = øvre grænse for normalområdet.
Abbreviations: SGOT=serum glutamic oxaloacetic transaminase; AST=aspartate aminotransferase; ULN=upper limit of the normal range.
ASAT eller ALAT > 8 x ULN eller
AST or ALT > 8 x ULN or
ASAT og/eller ALAT forhøjet til > 2,5 x ULN og total bilirubin forhøjet til ≥ 1,5 x ULN
Elevation of AST and/or ALT values to > 2.5 x ULN in conjunction with total bilirubin elevation to ≥ 1.5 x ULN
ASAT og/eller ALAT forhøjet til > 3 x ULN og total bilirubin forhøjet til ≥ 2 x ULN og ALKP
Elevation of AST and/or ALT values to > 3 x ULN in conjunction with an increase of total bilirubin to ≥ 2 x ULN and
ASAT,
AST, ALT,
ASAT, ALAT, GGT),
AST, ALT,
ASAT, basisk
Common
ASAT, basisk
Hepatic failure6
ASAT, basisk
Hepatic failure6 Jaundice6
ASAT, basisk fosfatase) Akut leverskade
Hepatic failure6 Jaundice6
ASAT-
AST (SGOT)
ASAT-
SGOT (AST)
ASAT-øgning
SGOT (AST)
ASAT-øgning
SGOT (AST) elevation
ASAT: > ULN (kan være normal eller < ULN, hvis total bilirubin er > ULN)
AST: >ULN (can be normal or < ULN if total bilirubin is >ULN)
ASAT: >ULN (kan være normal eller <ULN hvis total bilirubin er >ULN)
AST: >ULN (can be normal or < ULN if total bilirubin is >ULN)
ASAT: Aspartataminotransferase ALAT: Alaninaminotransferase ALKP: Basisk fosfatase ULN: Øvre normalgrænse
AST: Aspartate aminotransferase; ALT: Alanine aminotransferase ALKP: Alkaline phosphatase; ULN: Upper limit normal
Ascaridia galli (L5 og voksne stadier)
Ascaridia galli (L5 and adult stages)
Ascaridia galli (L5 og voksne stadier)
Ascaridia galli (L5 and adult stages);
Ascaris suum (voksne, intestinale og migrerende larvestadier)
Ascaris suum (adult and intestinal and migrating larval stages);
ascites, gastrointestinal ulceration og perforering, inflammation i mave-tarm-kanalen (hvilket som helst sted), stomatitis, dyspepsi, abdominal distension, orofaryngeal tørhed
ascites, gastrointestinal ulceration and perforation, gastrointestinal tract inflammation (any site), stomatitis, dyspepsia, abdominal distension, oropharyngeal dryness